Antibodies utilizing VL6-57 light chains target a convergent cryptic epitope on SARS-CoV-2 spike protein and potentially drive the genesis of Omicron variants
2024-08-31
发表期刊NATURE COMMUNICATIONS (IF:14.7[JCR-2023],16.1[5-Year])
ISSN2041-1723
EISSN2041-1723
卷号15期号:1
发表状态已发表
DOI10.1038/s41467-024-51770-3
摘要

["Continued evolution of SARS-CoV-2 generates variants to challenge antibody immunity established by infection and vaccination. A connection between population immunity and genesis of virus variants has long been suggested but its molecular basis remains poorly understood. Here, we identify a class of SARS-CoV-2 neutralizing public antibodies defined by their shared usage of VL6-57 light chains. Although heavy chains of diverse genotypes are utilized, convergent HCDR3 rearrangements have been observed among these public antibodies to cooperate with germline VL6-57 LCDRs to target a convergent epitope defined by RBD residues S371-S373-S375. Antibody repertoire analysis identifies that this class of VL6-57 antibodies is present in SARS-CoV-2-naive individuals and is clonally expanded in most COVID-19 patients. We confirm that Omicron-specific substitutions at S371, S373 and S375 mediate escape of antibodies of the VL6-57 class. These findings support that this class of public antibodies constitutes a potential immune pressure promoting the introduction of S371L/F-S373P-S375F in Omicron variants. The results provide further molecular evidence to support that antigenic evolution of SARS-CoV-2 is driven by antibody mediated population immunity.","Convergence of heavy or light chains in antibodies recognising pathogens could drive mutations in these pathogens. Here the authors examine antibodies against SARS-CoV-2 and find that a conserved VL6-57 light chain recognising a conserved motif in the spike protein is associated with virus mutations and could drive changes in SARS-CoV-2 omicron variants."]

URL查看原文
收录类别SCI
语种英语
资助项目SUSTech[
WOS研究方向Science & Technology - Other Topics
WOS类目Multidisciplinary Sciences
WOS记录号WOS:001303791200028
出版者NATURE PORTFOLIO
引用统计
正在获取...
文献类型期刊论文
条目标识符https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/424418
专题免疫化学研究所
免疫化学研究所_特聘教授组_赵金存组
通讯作者He, Jun; Chen, Ling; Zhao, Jincun; Xiong, Xiaoli
作者单位
1.Guangzhou Med Univ, Affiliated Hosp 1, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth,State Key Lab Resp Dis, Guangzhou, Peoples R China
2.Guangzhou Med Univ, Affiliated Hosp 5, Therapy & Rehabil Guangdong Higher Educ Inst, Key Lab Biol Targeting Diag, Guangzhou, Peoples R China
3.Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangdong Prov Key Lab Stem Cell & Regenerat Med, Guangdong Hong Kong Joint Lab Stem Cell & Regenera, Guangzhou 510530, Peoples R China
4.Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou, Peoples R China
5.Guangzhou Natl Lab, Guangzhou, Peoples R China
6.Univ Chinese Acad Sci, Beijing, Peoples R China
7.Guangzhou Regenerat Med & Hlth Guangdong Lab, Bioland Lab, Guangzhou, Peoples R China
8.ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Sch Life Sci & Technol, Shanghai, Peoples R China
通讯作者单位免疫化学研究所
推荐引用方式
GB/T 7714
Yan, Qihong,Gao, Xijie,Liu, Banghui,et al. Antibodies utilizing VL6-57 light chains target a convergent cryptic epitope on SARS-CoV-2 spike protein and potentially drive the genesis of Omicron variants[J]. NATURE COMMUNICATIONS,2024,15(1).
APA Yan, Qihong.,Gao, Xijie.,Liu, Banghui.,Hou, Ruitian.,He, Ping.,...&Xiong, Xiaoli.(2024).Antibodies utilizing VL6-57 light chains target a convergent cryptic epitope on SARS-CoV-2 spike protein and potentially drive the genesis of Omicron variants.NATURE COMMUNICATIONS,15(1).
MLA Yan, Qihong,et al."Antibodies utilizing VL6-57 light chains target a convergent cryptic epitope on SARS-CoV-2 spike protein and potentially drive the genesis of Omicron variants".NATURE COMMUNICATIONS 15.1(2024).
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Yan, Qihong]的文章
[Gao, Xijie]的文章
[Liu, Banghui]的文章
百度学术
百度学术中相似的文章
[Yan, Qihong]的文章
[Gao, Xijie]的文章
[Liu, Banghui]的文章
必应学术
必应学术中相似的文章
[Yan, Qihong]的文章
[Gao, Xijie]的文章
[Liu, Banghui]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。